 | • レポートコード：MRC2312MG09864 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、158ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥455,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥682,500 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のCD20標的薬市場規模と予測を収録しています。・世界のCD20標的薬市場：売上、2018年-2023年、2024年-2029年 ・世界のCD20標的薬市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のCD20標的薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「CD20ターゲット」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 CD20標的薬のグローバル主要企業は、Roche、 Sanofi、 Novartis、 TG Therapeutics、 AbbVie、 Genmab、 PT Kalbe Genexine Biologics、 Amgen, Inc.、 Pfizer Inc.、 Sandoz, Inc.、 Celltrion, Inc.、 Biocad Medical, Inc.、 mAbxience SA、 Hetero Drugs Ltd.、 Aryogen Pharmed、 Biosidus SA、 Probiomed SA de CV、 Henlius、 Innovent、 CHIATAI TIANOING、 CASI Pharmaceuticals、 SinoCellTech、 BioRayなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、CD20標的薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のCD20標的薬市場：タイプ別、2018年-2023年、2024年-2029年 世界のCD20標的薬市場：タイプ別市場シェア、2022年 ・CD20ターゲット、CD20+CD3ターゲット 世界のCD20標的薬市場：用途別、2018年-2023年、2024年-2029年 世界のCD20標的薬市場：用途別市場シェア、2022年 ・関節リウマチ、慢性リンパ性白血病、リンパ腫、その他 世界のCD20標的薬市場：地域・国別、2018年-2023年、2024年-2029年 世界のCD20標的薬市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるCD20標的薬のグローバル売上、2018年-2023年 ・主要企業におけるCD20標的薬のグローバル売上シェア、2022年 ・主要企業におけるCD20標的薬のグローバル販売量、2018年-2023年 ・主要企業におけるCD20標的薬のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Roche、 Sanofi、 Novartis、 TG Therapeutics、 AbbVie、 Genmab、 PT Kalbe Genexine Biologics、 Amgen, Inc.、 Pfizer Inc.、 Sandoz, Inc.、 Celltrion, Inc.、 Biocad Medical, Inc.、 mAbxience SA、 Hetero Drugs Ltd.、 Aryogen Pharmed、 Biosidus SA、 Probiomed SA de CV、 Henlius、 Innovent、 CHIATAI TIANOING、 CASI Pharmaceuticals、 SinoCellTech、 BioRay ************************************************************* ・調査・分析レポートの概要 CD20標的薬市場の定義 市場セグメント 世界のCD20標的薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のCD20標的薬市場規模 世界のCD20標的薬市場規模：2022年 VS 2029年 世界のCD20標的薬市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのCD20標的薬の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のCD20標的薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：CD20ターゲット、CD20+CD3ターゲット CD20標的薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：関節リウマチ、慢性リンパ性白血病、リンパ腫、その他 CD20標的薬の用途別グローバル売上・予測 ・地域別市場分析 地域別CD20標的薬市場規模 2022年と2029年 地域別CD20標的薬売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Roche、 Sanofi、 Novartis、 TG Therapeutics、 AbbVie、 Genmab、 PT Kalbe Genexine Biologics、 Amgen, Inc.、 Pfizer Inc.、 Sandoz, Inc.、 Celltrion, Inc.、 Biocad Medical, Inc.、 mAbxience SA、 Hetero Drugs Ltd.、 Aryogen Pharmed、 Biosidus SA、 Probiomed SA de CV、 Henlius、 Innovent、 CHIATAI TIANOING、 CASI Pharmaceuticals、 SinoCellTech、 BioRay ... |
This research report provides a comprehensive analysis of the CD20 Target Drug market, focusing on the current trends, market dynamics, and future prospects. The report explores the global CD20 Target Drug market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of CD20 Target Drug, challenges faced by the industry, and potential opportunities for market players.
The global CD20 Target Drug market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The CD20 Target Drug market presents opportunities for various stakeholders, including Rheumatoid Arthritis, Chronic Lymphocytic Leukemia. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in CD20 Target Drug market. Additionally, the growing consumer demand present avenues for market expansion.
The global CD20 Target Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the CD20 Target Drug market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the CD20 Target Drug market.
Market Overview: The report provides a comprehensive overview of the CD20 Target Drug market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., CD20 Target, CD20+CD3 Target), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the CD20 Target Drug market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the CD20 Target Drug market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the CD20 Target Drug market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the CD20 Target Drug market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the CD20 Target Drug market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the CD20 Target Drug market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for CD20 Target Drug, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the CD20 Target Drug market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
CD20 Target Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
CD20 Target
CD20+CD3 Target
Market segment by Application
Rheumatoid Arthritis
Chronic Lymphocytic Leukemia
Lymphoma
Other
Global CD20 Target Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Roche
Sanofi
Novartis
TG Therapeutics
AbbVie
Genmab
PT Kalbe Genexine Biologics
Amgen, Inc.
Pfizer Inc.
Sandoz, Inc.
Celltrion, Inc.
Biocad Medical, Inc.
mAbxience SA
Hetero Drugs Ltd.
Aryogen Pharmed
Biosidus SA
Probiomed SA de CV
Henlius
Innovent
CHIATAI TIANOING
CASI Pharmaceuticals
SinoCellTech
BioRay
Outline of Major Chapters:
Chapter 1: Introduces the definition of CD20 Target Drug, market overview.
Chapter 2: Global CD20 Target Drug market size in revenue and volume.
Chapter 3: Detailed analysis of CD20 Target Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of CD20 Target Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global CD20 Target Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 CD20 Target Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global CD20 Target Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global CD20 Target Drug Overall Market Size
2.1 Global CD20 Target Drug Market Size: 2022 VS 2029
2.2 Global CD20 Target Drug Revenue, Prospects & Forecasts: 2018-2029
2.3 Global CD20 Target Drug Sales: 2018-2029
3 Company Landscape
3.1 Top CD20 Target Drug Players in Global Market
3.2 Top Global CD20 Target Drug Companies Ranked by Revenue
3.3 Global CD20 Target Drug Revenue by Companies
3.4 Global CD20 Target Drug Sales by Companies
3.5 Global CD20 Target Drug Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 CD20 Target Drug Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers CD20 Target Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 CD20 Target Drug Players in Global Market
3.8.1 List of Global Tier 1 CD20 Target Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 CD20 Target Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global CD20 Target Drug Market Size Markets, 2022 & 2029
4.1.2 CD20 Target
4.1.3 CD20+CD3 Target
4.2 By Type – Global CD20 Target Drug Revenue & Forecasts
4.2.1 By Type – Global CD20 Target Drug Revenue, 2018-2023
4.2.2 By Type – Global CD20 Target Drug Revenue, 2024-2029
4.2.3 By Type – Global CD20 Target Drug Revenue Market Share, 2018-2029
4.3 By Type – Global CD20 Target Drug Sales & Forecasts
4.3.1 By Type – Global CD20 Target Drug Sales, 2018-2023
4.3.2 By Type – Global CD20 Target Drug Sales, 2024-2029
4.3.3 By Type – Global CD20 Target Drug Sales Market Share, 2018-2029
4.4 By Type – Global CD20 Target Drug Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global CD20 Target Drug Market Size, 2022 & 2029
5.1.2 Rheumatoid Arthritis
5.1.3 Chronic Lymphocytic Leukemia
5.1.4 Lymphoma
5.1.5 Other
5.2 By Application – Global CD20 Target Drug Revenue & Forecasts
5.2.1 By Application – Global CD20 Target Drug Revenue, 2018-2023
5.2.2 By Application – Global CD20 Target Drug Revenue, 2024-2029
5.2.3 By Application – Global CD20 Target Drug Revenue Market Share, 2018-2029
5.3 By Application – Global CD20 Target Drug Sales & Forecasts
5.3.1 By Application – Global CD20 Target Drug Sales, 2018-2023
5.3.2 By Application – Global CD20 Target Drug Sales, 2024-2029
5.3.3 By Application – Global CD20 Target Drug Sales Market Share, 2018-2029
5.4 By Application – Global CD20 Target Drug Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global CD20 Target Drug Market Size, 2022 & 2029
6.2 By Region – Global CD20 Target Drug Revenue & Forecasts
6.2.1 By Region – Global CD20 Target Drug Revenue, 2018-2023
6.2.2 By Region – Global CD20 Target Drug Revenue, 2024-2029
6.2.3 By Region – Global CD20 Target Drug Revenue Market Share, 2018-2029
6.3 By Region – Global CD20 Target Drug Sales & Forecasts
6.3.1 By Region – Global CD20 Target Drug Sales, 2018-2023
6.3.2 By Region – Global CD20 Target Drug Sales, 2024-2029
6.3.3 By Region – Global CD20 Target Drug Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America CD20 Target Drug Revenue, 2018-2029
6.4.2 By Country – North America CD20 Target Drug Sales, 2018-2029
6.4.3 US CD20 Target Drug Market Size, 2018-2029
6.4.4 Canada CD20 Target Drug Market Size, 2018-2029
6.4.5 Mexico CD20 Target Drug Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe CD20 Target Drug Revenue, 2018-2029
6.5.2 By Country – Europe CD20 Target Drug Sales, 2018-2029
6.5.3 Germany CD20 Target Drug Market Size, 2018-2029
6.5.4 France CD20 Target Drug Market Size, 2018-2029
6.5.5 U.K. CD20 Target Drug Market Size, 2018-2029
6.5.6 Italy CD20 Target Drug Market Size, 2018-2029
6.5.7 Russia CD20 Target Drug Market Size, 2018-2029
6.5.8 Nordic Countries CD20 Target Drug Market Size, 2018-2029
6.5.9 Benelux CD20 Target Drug Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia CD20 Target Drug Revenue, 2018-2029
6.6.2 By Region – Asia CD20 Target Drug Sales, 2018-2029
6.6.3 China CD20 Target Drug Market Size, 2018-2029
6.6.4 Japan CD20 Target Drug Market Size, 2018-2029
6.6.5 South Korea CD20 Target Drug Market Size, 2018-2029
6.6.6 Southeast Asia CD20 Target Drug Market Size, 2018-2029
6.6.7 India CD20 Target Drug Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America CD20 Target Drug Revenue, 2018-2029
6.7.2 By Country – South America CD20 Target Drug Sales, 2018-2029
6.7.3 Brazil CD20 Target Drug Market Size, 2018-2029
6.7.4 Argentina CD20 Target Drug Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa CD20 Target Drug Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa CD20 Target Drug Sales, 2018-2029
6.8.3 Turkey CD20 Target Drug Market Size, 2018-2029
6.8.4 Israel CD20 Target Drug Market Size, 2018-2029
6.8.5 Saudi Arabia CD20 Target Drug Market Size, 2018-2029
6.8.6 UAE CD20 Target Drug Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche CD20 Target Drug Major Product Offerings
7.1.4 Roche CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 Sanofi
7.2.1 Sanofi Company Summary
7.2.2 Sanofi Business Overview
7.2.3 Sanofi CD20 Target Drug Major Product Offerings
7.2.4 Sanofi CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.2.5 Sanofi Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis CD20 Target Drug Major Product Offerings
7.3.4 Novartis CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.3.5 Novartis Key News & Latest Developments
7.4 TG Therapeutics
7.4.1 TG Therapeutics Company Summary
7.4.2 TG Therapeutics Business Overview
7.4.3 TG Therapeutics CD20 Target Drug Major Product Offerings
7.4.4 TG Therapeutics CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.4.5 TG Therapeutics Key News & Latest Developments
7.5 AbbVie
7.5.1 AbbVie Company Summary
7.5.2 AbbVie Business Overview
7.5.3 AbbVie CD20 Target Drug Major Product Offerings
7.5.4 AbbVie CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.5.5 AbbVie Key News & Latest Developments
7.6 Genmab
7.6.1 Genmab Company Summary
7.6.2 Genmab Business Overview
7.6.3 Genmab CD20 Target Drug Major Product Offerings
7.6.4 Genmab CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.6.5 Genmab Key News & Latest Developments
7.7 PT Kalbe Genexine Biologics
7.7.1 PT Kalbe Genexine Biologics Company Summary
7.7.2 PT Kalbe Genexine Biologics Business Overview
7.7.3 PT Kalbe Genexine Biologics CD20 Target Drug Major Product Offerings
7.7.4 PT Kalbe Genexine Biologics CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.7.5 PT Kalbe Genexine Biologics Key News & Latest Developments
7.8 Amgen, Inc.
7.8.1 Amgen, Inc. Company Summary
7.8.2 Amgen, Inc. Business Overview
7.8.3 Amgen, Inc. CD20 Target Drug Major Product Offerings
7.8.4 Amgen, Inc. CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.8.5 Amgen, Inc. Key News & Latest Developments
7.9 Pfizer Inc.
7.9.1 Pfizer Inc. Company Summary
7.9.2 Pfizer Inc. Business Overview
7.9.3 Pfizer Inc. CD20 Target Drug Major Product Offerings
7.9.4 Pfizer Inc. CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.9.5 Pfizer Inc. Key News & Latest Developments
7.10 Sandoz, Inc.
7.10.1 Sandoz, Inc. Company Summary
7.10.2 Sandoz, Inc. Business Overview
7.10.3 Sandoz, Inc. CD20 Target Drug Major Product Offerings
7.10.4 Sandoz, Inc. CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.10.5 Sandoz, Inc. Key News & Latest Developments
7.11 Celltrion, Inc.
7.11.1 Celltrion, Inc. Company Summary
7.11.2 Celltrion, Inc. Business Overview
7.11.3 Celltrion, Inc. CD20 Target Drug Major Product Offerings
7.11.4 Celltrion, Inc. CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.11.5 Celltrion, Inc. Key News & Latest Developments
7.12 Biocad Medical, Inc.
7.12.1 Biocad Medical, Inc. Company Summary
7.12.2 Biocad Medical, Inc. Business Overview
7.12.3 Biocad Medical, Inc. CD20 Target Drug Major Product Offerings
7.12.4 Biocad Medical, Inc. CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.12.5 Biocad Medical, Inc. Key News & Latest Developments
7.13 mAbxience SA
7.13.1 mAbxience SA Company Summary
7.13.2 mAbxience SA Business Overview
7.13.3 mAbxience SA CD20 Target Drug Major Product Offerings
7.13.4 mAbxience SA CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.13.5 mAbxience SA Key News & Latest Developments
7.14 Hetero Drugs Ltd.
7.14.1 Hetero Drugs Ltd. Company Summary
7.14.2 Hetero Drugs Ltd. Business Overview
7.14.3 Hetero Drugs Ltd. CD20 Target Drug Major Product Offerings
7.14.4 Hetero Drugs Ltd. CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.14.5 Hetero Drugs Ltd. Key News & Latest Developments
7.15 Aryogen Pharmed
7.15.1 Aryogen Pharmed Company Summary
7.15.2 Aryogen Pharmed Business Overview
7.15.3 Aryogen Pharmed CD20 Target Drug Major Product Offerings
7.15.4 Aryogen Pharmed CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.15.5 Aryogen Pharmed Key News & Latest Developments
7.16 Biosidus SA
7.16.1 Biosidus SA Company Summary
7.16.2 Biosidus SA Business Overview
7.16.3 Biosidus SA CD20 Target Drug Major Product Offerings
7.16.4 Biosidus SA CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.16.5 Biosidus SA Key News & Latest Developments
7.17 Probiomed SA de CV
7.17.1 Probiomed SA de CV Company Summary
7.17.2 Probiomed SA de CV Business Overview
7.17.3 Probiomed SA de CV CD20 Target Drug Major Product Offerings
7.17.4 Probiomed SA de CV CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.17.5 Probiomed SA de CV Key News & Latest Developments
7.18 Henlius
7.18.1 Henlius Company Summary
7.18.2 Henlius Business Overview
7.18.3 Henlius CD20 Target Drug Major Product Offerings
7.18.4 Henlius CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.18.5 Henlius Key News & Latest Developments
7.19 Innovent
7.19.1 Innovent Company Summary
7.19.2 Innovent Business Overview
7.19.3 Innovent CD20 Target Drug Major Product Offerings
7.19.4 Innovent CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.19.5 Innovent Key News & Latest Developments
7.20 CHIATAI TIANOING
7.20.1 CHIATAI TIANOING Company Summary
7.20.2 CHIATAI TIANOING Business Overview
7.20.3 CHIATAI TIANOING CD20 Target Drug Major Product Offerings
7.20.4 CHIATAI TIANOING CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.20.5 CHIATAI TIANOING Key News & Latest Developments
7.21 CASI Pharmaceuticals
7.21.1 CASI Pharmaceuticals Company Summary
7.21.2 CASI Pharmaceuticals Business Overview
7.21.3 CASI Pharmaceuticals CD20 Target Drug Major Product Offerings
7.21.4 CASI Pharmaceuticals CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.21.5 CASI Pharmaceuticals Key News & Latest Developments
7.22 SinoCellTech
7.22.1 SinoCellTech Company Summary
7.22.2 SinoCellTech Business Overview
7.22.3 SinoCellTech CD20 Target Drug Major Product Offerings
7.22.4 SinoCellTech CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.22.5 SinoCellTech Key News & Latest Developments
7.23 BioRay
7.23.1 BioRay Company Summary
7.23.2 BioRay Business Overview
7.23.3 BioRay CD20 Target Drug Major Product Offerings
7.23.4 BioRay CD20 Target Drug Sales and Revenue in Global (2018-2023)
7.23.5 BioRay Key News & Latest Developments
8 Global CD20 Target Drug Production Capacity, Analysis
8.1 Global CD20 Target Drug Production Capacity, 2018-2029
8.2 CD20 Target Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global CD20 Target Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 CD20 Target Drug Supply Chain Analysis
10.1 CD20 Target Drug Industry Value Chain
10.2 CD20 Target Drug Upstream Market
10.3 CD20 Target Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 CD20 Target Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer